We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Test Rapidly Identifies Platelet Function Defects

By LabMedica International staff writers
Posted on 06 Aug 2014
A multisurface and multiparameter flow assay to characterize thrombus formation in whole blood from healthy subjects and patients with platelet function deficiencies has been created. More...


Parallel-plate flow chambers have been used for the last two decades to measure platelet adhesion and activation under arterial or venous flow conditions, in particular using surfaces such as extracellular matrix or collagen, but there is a need for further standardization of devices, protocols and measurement parameters.

A team of scientists led by those at Maastricht University (The Netherlands) obtained blood samples from healthy donors and patients who all had a well-defined platelet deficiency and mild bleeding tendency. Microspot-coated coverslips were mounted onto a transparent parallel-plate flow chamber (50 μm depth, 3 mm width and 20 mm length), and pre-rinsed. Anticoagulated whole-blood samples were perfused through the flow chamber for a time period sufficient for full-thrombus formation on collagen I spots and adherence labeled with a fluorescence marker.

A systematic comparison is made of 52 adhesive surfaces with components activating the main platelet-adhesive receptors, and of eight output parameters reflecting distinct stages of thrombus formation. Three types of thrombus formation can be identified with a predicted hierarchy of the following receptors: glycoprotein (GP) VI, C-type lectin-like receptor-2 (CLEC-2) > GPIb > α6β1 αIIbβ3 > α2β1 > CD36, α5β1, αvβ3. Application with patient blood reveals distinct abnormalities in thrombus formation in patients with severe combined immune deficiency, Glanzmann’s thrombasthenia, Hermansky–Pudlak syndrome, May–Hegglin anomaly or grey platelet syndrome. This test may be useful for the diagnosis of patients with suspected bleeding disorders or a pro-thrombotic tendency.

Johan W.M. Heemskerk, PhD, a professor and a senior author of the study said, “To develop this test we collected information on thrombosis formation in a flow chamber with flowing blood. This has never been done before on such a large scale. We can easily determine what’s wrong with the patient by counting the number of platelets in a few drops of blood. If there’s an active bleed, the platelets trigger the coagulation process to stem the bleeding. The opposite is true with thrombosis: in that case, the platelets are overactive and could cause a stroke or a heart attack.” The study was published on July 16, 2014, in the journal Nature Communications.

Related Links:

Maastricht University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.